Literature DB >> 35380240

Lymphocyte transformation test reveals low prevalence of true metal hypersensitivity among pre-operative total knee arthroplasty patients.

Tarek Boutefnouchet1,2, Francis Vallières3, Josee Delisle3, Mohamed Benderdour3, Julio C Fernandes3.   

Abstract

PURPOSE: The aims of this study were to determine the prevalence of metal hypersensitivity, and identify pre-operative factors which could predict susceptibility to hypersensitivity reactions among patients scheduled for primary total knee arthroplasty (TKA). The present study used a testing method consistent with the recognised biological response to metals.
METHODS: A prospective cross-sectional analysis of 220 patients was conducted. All patients received a testing protocol using lymphocyte transformation test to evaluate reactivity to possible contents of orthopaedic implants. Test response is interpreted as stimulation index (SI) values. A comprehensive questionnaire was used to evaluate prior exposure. Patients were categorised according to SI values and the odds ratios (OR) were calculated as comparative effect measure for each predetermined prior exposure factor.
RESULTS: The prevalence of metal sensitivity response was 28% (n = 61) among patients with susceptibility to at least one agent (SI = 2 to 4.9), and 3.2% (n = 7) among patients with true hypersensitivity (SI ≥ 5). The population-weighted prevalence, adjusted for sampling weights of symptomatic knee osteoarthritis, was SI ≥ 5 = 4.7% (95% CI 0.4-11.8%) and SI ≥ 2 = 35.2% (95% CI 24.8-48.6%). Stimulation index levels of response to materials were markedly varied with the highest being aluminium. Female sex, smoking history, cutaneous reaction to jewellery, occupational exposure, and dental procedures were among factors shown to increase the odds of having higher reactivity response to tested metals. Nevertheless, patients with well-functioning prior contralateral TKA did not appear at greater risk of having either sensitivity or susceptibility with odds ratio (OR) = 0.2 (95% CI 0.01-3.2), p: NS and OR = 0.6 (95% CI 0.3-1.2), p: NS, respectively. Prior positive patch test was neither predictor of susceptibility to hypersensitivity OR = 1.2 (95% CI 0.6-2.6) p: NS nor predictor of true hypersensitivity OR = 0.7 (95% CI 0.08-6.1), p: NS.
CONCLUSION: Among patients scheduled for primary TKA with no prior clinical features of metal allergy the prevalence of true hypersensitivity to at least one metal is just over 3%. Patients are likely to encounter a material to which they have pre-existing susceptibility to hypersensitivity. With certain prior exposure factors, there was increased susceptibility to metal hypersensitivity reaction evoking an acquired condition. LEVEL OF EVIDENCE: Level II, prospective cross-sectional study.
© 2022. The Author(s) under exclusive licence to European Society of Sports Traumatology, Knee Surgery, Arthroscopy (ESSKA).

Entities:  

Keywords:  Arthroplasty; Hypersensitivity; Knee; Lymphocyte transformation test; Metal allergy; Prevalence

Year:  2022        PMID: 35380240     DOI: 10.1007/s00167-022-06951-2

Source DB:  PubMed          Journal:  Knee Surg Sports Traumatol Arthrosc        ISSN: 0942-2056            Impact factor:   4.342


  41 in total

1.  The epidemiology of revision total knee and hip arthroplasty in England and Wales: a comparative analysis with projections for the United States. A study using the National Joint Registry dataset.

Authors:  A Patel; G Pavlou; R E Mújica-Mota; A D Toms
Journal:  Bone Joint J       Date:  2015-08       Impact factor: 5.082

2.  Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030.

Authors:  Steven Kurtz; Kevin Ong; Edmund Lau; Fionna Mowat; Michael Halpern
Journal:  J Bone Joint Surg Am       Date:  2007-04       Impact factor: 5.284

3.  Prevalence of self-reported metal allergy in patients undergoing primary total knee arthroplasty.

Authors:  Adam D Bloemke; Henry D Clarke
Journal:  J Knee Surg       Date:  2014-06-20       Impact factor: 2.757

4.  Impact of the economic downturn on total joint replacement demand in the United States: updated projections to 2021.

Authors:  Steven M Kurtz; Kevin L Ong; Edmund Lau; Kevin J Bozic
Journal:  J Bone Joint Surg Am       Date:  2014-04-16       Impact factor: 5.284

5.  Patient-Reported Allergies Are Associated With Poorer Patient Satisfaction and Outcomes After Lower Extremity Arthroplasty: A Retrospective Cohort Study.

Authors:  Alexander S McLawhorn; Benjamin T Bjerke-Kroll; Jason L Blevins; Peter K Sculco; Yuo-yu Lee; Seth A Jerabek
Journal:  J Arthroplasty       Date:  2015-02-02       Impact factor: 4.757

Review 6.  Allergy in total knee arthroplasty: a review of the facts.

Authors:  S Middleton; A Toms
Journal:  Bone Joint J       Date:  2016-04       Impact factor: 5.082

Review 7.  Nickel, cobalt and chromium in consumer products: a role in allergic contact dermatitis?

Authors:  D A Basketter; G Briatico-Vangosa; W Kaestner; C Lally; W J Bontinck
Journal:  Contact Dermatitis       Date:  1993-01       Impact factor: 6.600

8.  Nickel, chromium and cobalt: the relevant allergens in allergic contact dermatitis. Comparative study between two periods: 1995-2002 and 2003-2015.

Authors:  Ida Duarte; Rodolfo Ferreira Mendonça; Karen Levy Korkes; Rosana Lazzarini; Mariana de Figueiredo Silva Hafner
Journal:  An Bras Dermatol       Date:  2018 Jan-Feb       Impact factor: 1.896

9.  Pain in a chromium-allergic patient with total knee arthroplasty: disappearance of symptoms after revision with a special surface-coated TKA--a case report.

Authors:  Marc Thomsen; Matthias Rozak; Peter Thomas
Journal:  Acta Orthop       Date:  2011-04-20       Impact factor: 3.717

10.  Metal release and metal allergy after total hip replacement with resurfacing versus conventional hybrid prosthesis.

Authors:  Klas Gustafson; Stig S Jakobsen; Nina D Lorenzen; Jacob P Thyssen; Jeanne D Johansen; Charlotte M Bonefeld; Maiken Stilling; Thomas Baad-Hansen; Kjeld Søballe
Journal:  Acta Orthop       Date:  2014-06-16       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.